Login to Your Account



Financings Roundup


Friday, April 6, 2012
• Nile Therapeutics Inc., of San Mateo, Calif., closed its previously announced registered direct offering, raising $1.34 million. The company sold 3.35 million shares of common stock and warrants to purchase an additional 2.5 million shares. Proceeds will help to fund a Phase II trial of cenderitide for heart failure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription